Page 101 - Read Online

Porcari et al. Vessel Plus 2022;6:33 https://dx.doi.org/10.20517/2574-1209.2021.134 Page 13 of 14

PubMed
50. Donnellan E, Elshazly MB, Vakamudi S, et al. No association between CHADS-VASc score and left atrial appendage thrombus in
patients with transthyretin amyloidosis. JACC Clin Electrophysiol 2019;5:1473-4. DOI PubMed
51. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation
2009;119:2490-7. DOI PubMed
52. Santarone M, Corrado G, Tagliagambe LM, et al. Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal
echocardiography. J Am Soc Echocardiogr 1999;12:533-6. DOI PubMed
53. Parsons C, Patel SI, Cha S, et al. CHA DS -VASc score: a predictor of thromboembolic events and mortality in patients with an
2 2
implantable monitoring device without atrial fibrillation. Mayo Clin Proc 2017;92:360-9. DOI PubMed PMC
54. Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol
2019;74:2638-51. DOI PubMed
55. Galat A, Guellich A, Bodez D, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J
2016;37:3525-31. DOI PubMed
56. Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and
prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 2016;9:e005066. DOI PubMed
57. Sperry BW, Jones BM, Vranian MN, Hanna M, Jaber WA. Recognizing transthyretin cardiac amyloidosis in patients with aortic
stenosis: impact on prognosis. JACC Cardiovasc Imaging 2016;9:904-6. DOI PubMed
58. Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J 2016;37:2645-57. DOI PubMed PMC
59. Monticelli FC, Kunz SN, Keller T, Bleiziffer S. Cardiac amyloidosis as a potential risk factor for transapical transcatheter aortic valve
implantation. J Card Surg 2014;29:623-4. DOI PubMed
60. Moreno R, Dobarro D, López de Sá E, et al. Cause of complete atrioventricular block after percutaneous aortic valve implantation:
insights from a necropsy study. Circulation 2009;120:e29-30. DOI PubMed
61. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.
QJM 1998;91:141-57. DOI PubMed
62. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart
Rhythm 2014;11:158-62. DOI PubMed
63. Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic
light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol
2009;104:990-4. DOI PubMed
64. Palladini G, Malamani G, Cò F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol
2001;24:1228-33. DOI PubMed
65. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol
2020;6:351-61. DOI PubMed
66. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of
patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with
ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). Endorsed by:
Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-867. DOI PubMed
67. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm
2018;15:e190-252. DOI PubMed
68. Ponikowski P, Voors AA, Anker SD, et al; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European
Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J
2016;37:2129-200. DOI PubMed
69. Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy
in patients with cardiac amyloidosis. Int J Cardiol 2016;222:562-8. DOI PubMed
70. Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J
Cardiovasc Electrophysiol 2013;24:793-8. DOI PubMed
71. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac
amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:235-40. DOI PubMed
72. Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J
2015;36:1098-105. DOI PubMed
73. Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol 2020;109:78-88.
DOI PubMed PMC
74. Damy T, Jaccard A, Guellich A, et al. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Amyloid
2016;23:194-202. DOI PubMed
75. Donnellan E, Wazni OM, Hanna M, Kanj M, Saliba WI, Jaber WA. Cardiac resynchronization therapy for transthyretin cardiac
amyloidosis. J Am Heart Assoc 2020;9:e017335. DOI PubMed PMC